Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles

被引:136
作者
Azarmi, Shirzad
Tao, Xia
Chen, Hua
Wang, Zhaolin
Finlay, Warren H.
Lobenberg, Raimar [1 ]
Roa, Wilson H.
机构
[1] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada
[2] Tabriz Univ Med Sci, Fac Pharm, Res Ctr Pharmaceut Nanotechnol, Tabriz, Iran
[3] Univ Alberta, Dept Oncol, Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[4] Univ Alberta, Dept Mech Engn, Edmonton, AB T6G 2G8, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
cytotoxicity; doxorubicin; nanoparticles; powder inhalation; spray-freeze drying; lung cancer cells;
D O I
10.1016/j.ijpharm.2006.03.052
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Regional drug delivery via dry powder inhalers offers many advantages in the management of pharmaceutical compounds for the prevention and treatment of respiratory diseases. In the present study, doxorubicin (DOX)-loaded nanoparticles were incorporated as colloidal drug delivery system into inhalable carrier particles using a spray-freeze-drying technique. The cytotoxic effects of free DOX, carrier particles containing blank nanoparticles or DOX-loaded nanopanicles on H460 and A549 lung cancer cells were assessed using a colorimetric XTT cell viability assay. The mean geometric carrier particle size of 10 +/- 4 mu m was determined using confocal laser scanning microscopy. DOX-loaded nanoparticles had a particle size of 173 +/- 43 nm after re-dissolving of the carrier particles. Compared to H460 cells, A549 cells showed less sensitivity to the treatment with free DOX The DOX-nanoparticles showed in both cell lines a higher cytotoxicity at the highest tested concentration compared to the blank nanoparticles and the free DOX. The cell uptake of free DOX and DOX delivered by nanoparticles was confirmed using confocal laser scanning microscopy. This study supports the approach of lung cancer treatment using nanoparticles in dry powder aerosol form. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:155 / 161
页数:7
相关论文
共 29 条
[1]  
ALYAUTDIN R, 1995, EUR J PHARM BIOPHARM, V41, P44
[2]   Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles [J].
Alyautdin, RN ;
Petrov, VE ;
Langer, K ;
Berthold, A ;
Kharkevich, DA ;
Kreuter, J .
PHARMACEUTICAL RESEARCH, 1997, 14 (03) :325-328
[3]   Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study [J].
Alyautdin, RN ;
Tezikov, EB ;
Ramge, P ;
Kharkevich, DA ;
Begley, DJ ;
Kreuter, J .
JOURNAL OF MICROENCAPSULATION, 1998, 15 (01) :67-74
[4]   Influence of the surfactant concentration on the body distribution of nanoparticles [J].
Araujo, L ;
Löbenberg, R ;
Kreuter, J .
JOURNAL OF DRUG TARGETING, 1999, 6 (05) :373-385
[5]  
Bácskay I, 2005, EUR J PHARM SCI, V25, pS46
[6]   DOXORUBICIN-LOADED NANOSPHERES BYPASS TUMOR-CELL MULTIDRUG RESISTANCE [J].
CUVIER, C ;
ROBLOTTREUPEL, L ;
MILLOT, JM ;
LIZARD, G ;
CHEVILLARD, S ;
MANFAIT, M ;
COUVREUR, P ;
POUPON, MF .
BIOCHEMICAL PHARMACOLOGY, 1992, 44 (03) :509-517
[7]   Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: Towards a mechanism of action [J].
deVerdiere, AC ;
Dubernet, C ;
Nemati, F ;
Soma, E ;
Appel, M ;
Ferte, J ;
Bernard, S ;
Puisieux, F ;
Couvreur, P .
BRITISH JOURNAL OF CANCER, 1997, 76 (02) :198-205
[8]  
FINLAY W, 2001, MECH INHALED PHARM A
[9]  
FINLAY WH, 2003, Patent No. 0025550013
[10]   Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma [J].
Gelperina, SE ;
Khalansky, AS ;
Skidan, IN ;
Smirnova, ZS ;
Bobruskin, AI ;
Severin, SE ;
Turowski, B ;
Zanella, FE ;
Kreuter, J .
TOXICOLOGY LETTERS, 2002, 126 (02) :131-141